Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

106.540
+1.110+1.05%

Trading Feb 18 09:51 ET

210.43BMarket Cap18.15P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)
TipRanks04:01 ET · Ratings
Novartis AG Rises Monday, Outperforms Market
Dow Jones12:16 ET
Key Deals This Week: Papa John's, Spirit Airlines, Novartis, Banco Santander and More
Seeking AlphaFeb 15 15:15 ET
Congressmember Shelley Moore Capito's New Portfolio Holdings
Quiver QuantitativeFeb 14 15:00 ET
Incyte Jumps Amid Takeover Speculation
Seeking AlphaFeb 13 15:03 ET
Express News | U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians
BenzingaFeb 13 13:16 ET

Comments

Asherboy88

Jan 27 07:41

Don't know why

$Novartis AG (NVS.US)$ why this stock keeps falling despite so many good news. Can someone enlighten pls

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

Stock_Drift

Dec 19, 2024 05:18

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

NVS Novartis AG

Trade Overview

Capital Trend

News

Comments

Trending Stocks